Format

Send to

Choose Destination
J Am Coll Cardiol. 2017 Jan 24;69(3):265-274. doi: 10.1016/j.jacc.2016.10.062.

Outcomes Among Older Patients Receiving Implantable Cardioverter-Defibrillators for Secondary Prevention: From the NCDR ICD Registry.

Author information

1
Department of Medicine, University of Colorado, Denver, Colorado.
2
Division of Cardiology, University of Colorado, Denver, Colorado; Colorado Cardiovascular Outcomes Research Group, Denver, Colorado.
3
Division of Cardiology, University of Colorado, Denver, Colorado; Colorado Cardiovascular Outcomes Research Group, Denver, Colorado; Denver Health Medical Center, Denver, Colorado.
4
Division of Cardiology, Duke University, Durham, North Carolina.
5
Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut; Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut.
6
Division of Cardiology, University of Massachusetts Medical School, Worcester, Massachusetts.
7
Division of Cardiology, University of Colorado, Denver, Colorado; Colorado Cardiovascular Outcomes Research Group, Denver, Colorado. Electronic address: fred.masoudi@ucdenver.edu.

Erratum in

Abstract

BACKGROUND:

Clinical trials of implantable cardioverter-defibrillators (ICDs) for secondary prevention of sudden cardiac death were conducted nearly 2 decades ago and enrolled few older patients.

OBJECTIVES:

This study assessed morbidity and mortality of older patients receiving ICDs for secondary prevention in contemporary clinical practice.

METHODS:

We identified 12,420 Medicare beneficiaries from the National Cardiovascular Data Registry ICD Registry undergoing first-time secondary prevention ICD implantation between 2006 and 2009 in 956 U.S. hospitals. Risks of death, hospitalization, and admission to a skilled nursing facility (SNF) were assessed over 2 years in age strata (65 to 69, 70 to 74, 75 to 79, and ≥80 years of age) using Medicare claims. The adjusted association between age and outcomes was evaluated using multivariable models.

RESULTS:

The mean age was 75 years at the time of implantation; 25.3% were <70 years of age and 25.7% were ≥80 years of age. Overall, the risk of death at 2 years was 21.8%, ranging from 14.7% among those <70 years of age to 28.9% among those ≥80 years of age (adjusted risk ratio [aRR]: 2.01; 95% confidence interval [CI]: 1.85 to 2.33; p for trend <0.001). The cumulative incidence of hospitalizations was 65.4%, ranging from 60.5% in those <70 years of age to 71.5% in those ≥80 years of age (aRR: 1.27; 95% CI: 1.19 to 1.36; p for trend <0.001). The cumulative incidence of admission to a SNF ranged from 13.1% among those <70 years of age to 31.9% among those ≥80 years of age (aRR: 2.67; 95% CI: 2.37 to 3.01; p for trend <0.001); SNF admission risk was highest in the first 30 days.

CONCLUSIONS:

Almost 4 in 5 older patients receiving a secondary prevention ICD survives at least 2 years. High hospitalization and SNF admission rates, particularly among the oldest patients, identify substantial care needs after device implantation.

KEYWORDS:

arrhythmia; elderly; electrophysiology

Comment in

PMID:
28104069
DOI:
10.1016/j.jacc.2016.10.062
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center